BI Asset Management Fondsmaeglerselskab A S Purchases 2,871 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

BI Asset Management Fondsmaeglerselskab A S boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,449 shares of the medical equipment provider's stock after acquiring an additional 2,871 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Zimmer Biomet were worth $998,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB lifted its holdings in Zimmer Biomet by 7.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider's stock worth $669,000 after buying an additional 442 shares during the period. B. Riley Wealth Advisors Inc. lifted its stake in Zimmer Biomet by 17.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider's stock worth $260,000 after acquiring an additional 358 shares during the period. GAMMA Investing LLC boosted its holdings in Zimmer Biomet by 67.6% in the fourth quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider's stock valued at $243,000 after acquiring an additional 927 shares in the last quarter. Central Pacific Bank Trust Division increased its position in Zimmer Biomet by 7.4% during the 4th quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider's stock valued at $1,534,000 after purchasing an additional 1,000 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Zimmer Biomet by 3.9% in the 4th quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider's stock worth $1,732,000 after purchasing an additional 609 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZBH shares. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.95% of the company's stock.

Zimmer Biomet Stock Up 0.1 %

Shares of ZBH traded up $0.08 on Monday, hitting $101.59. 185,739 shares of the stock traded hands, compared to its average volume of 1,663,936. The company has a market capitalization of $20.10 billion, a PE ratio of 22.87, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a one year low of $93.10 and a one year high of $123.96. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business has a 50 day simple moving average of $105.81 and a 200 day simple moving average of $106.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.